Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acasti Pharma (ACST)

Acasti Pharma (ACST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 51,205
  • Shares Outstanding, K 89,834
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,290 K
  • 60-Month Beta 1.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.36
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/14/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.06
  • Number of Estimates 3
  • High Estimate -0.02
  • Low Estimate -0.09
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +64.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.48 +19.50%
on 02/10/20
0.91 -37.36%
on 01/15/20
-0.37 (-39.36%)
since 01/14/20
3-Month
0.48 +19.50%
on 02/10/20
3.08 -81.49%
on 12/23/19
-1.38 (-70.77%)
since 11/14/19
52-Week
0.48 +19.50%
on 02/10/20
3.08 -81.49%
on 12/23/19
-0.35 (-38.04%)
since 02/14/19

Most Recent Stories

More News
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre...

ACST : 0.57 (-1.55%)
ACST.VN : 0.760 (unch)
Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.57 (-1.55%)
ACST.VN : 0.760 (unch)
Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre

Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1

ACST : 0.57 (-1.55%)
ACST.VN : 0.760 (unch)
AstraZeneca to End Phase III Study on Fish Oil Heart Drug

AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee

MRK : 82.65 (+0.83%)
AZN : 47.85 (-3.00%)
AMRN : 17.62 (-0.40%)
ACST : 0.57 (-1.55%)
Neptune Provides Updates on Non-Core Investments

Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (Nasdaq: NEPT) (TSX: NEPT), a health and wellness company focused on extraction, purification and formulation of cannabinoids, would like to...

NEPT : 1.89 (+1.61%)
NEPT.TO : 2.49 (+0.81%)
ACST : 0.57 (-1.55%)
Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride levels among...

ACST : 0.57 (-1.55%)
ACST.VN : 0.760 (unch)
IIROC Trading Resumption - ACST

Trading resumes in:

ACST : 0.57 (-1.55%)
ACST.VN : 0.760 (unch)
Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Expects to report Trilogy 1 topline results in January 2020

ACST : 0.57 (-1.55%)
ACST.VN : 0.760 (unch)
IIROC Trading Halt - ACST

The following issues have been halted by IIROC:

ACST : 0.57 (-1.55%)
ACST.VN : 0.760 (unch)
Why the U.S. Remains the Largest Market for Medical Devices

Back in the end of 2018, a report from Moody's said that 2019 should be a standout year for the medical device industry. They added that revenue growth for device companies would be driven through innovation...

SOLY : 12.60 (-1.49%)
ATEC : 6.89 (+7.66%)
MDT : 117.33 (+0.43%)
IMGN : 6.80 (+26.87%)
ACST : 0.57 (-1.55%)
ACST.VN : 0.760 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade ACST with:

Business Summary

Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R)...

See More

Key Turning Points

2nd Resistance Point 0.74
1st Resistance Point 0.66
Last Price 0.57
1st Support Level 0.52
2nd Support Level 0.46

See More

52-Week High 3.08
Fibonacci 61.8% 2.09
Fibonacci 50% 1.78
Fibonacci 38.2% 1.47
Last Price 0.57
52-Week Low 0.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar